Diabetes Care recently published online before print full results from a phase 2 trial of Mesoblast’s mesenchymal precursor cell (MPC) treatment for type 2 diabetes aimed at reducing inflammation. Topline results were released at the end of 2013. The multicenter 12-week, single-blind, dose escalation trial randomized 61 type 2 diabetes patients (mean A1c of 8.3% and diabetes duration of 10 years) to receive a single intravenous infusion of 0.3, 1.0, or 2.0 million MPCs/kg or placebo. After 12 weeks, the MPC treatment produced modest, dose-dependent A1c reductions compared to placebo (0.0%, -0.1%, and -0.3% respectively for the 0.3, 1.0, and 2.0 million MPCs/kg doses). The greatest difference in A1c was seen in the highest dose group at week eight with a 0.4% reduction vs. placebo (P<0.05). At 12 weeks, five (33.3%) subjects in the highest dose group had achieved the <7% A1c target compared to none in the placebo group (P<0.05). As is commonly seen, the treatment seemed to demonstrate greater efficacy in patients with starting A1c ≥8% – a 0.4% reduction in the highest dose group compared to a 0.2% reduction in patients with a starting A1c <8%. There was no observed difference in fasting glucose levels, suggesting this treatment may be targeting postprandial effects. Crucially, the study saw no serious adverse events, serious hypoglycemia, or discontinuations over the 12-week trial period, meeting its primary endpoint. In addition, no immune responses against MPC donor antigens were identified in any subject. We are glad to see these reassuring safety results and look forward to seeing efficacy results from more robust trials in the future. Stem cell treatments are a hot topic in diabetes treatment right now, though most therapies in the pipeline are focused on type 1 diabetes (see Melton group and ViaCyte). Mesoblast is also currently in phase 2 trials investigating MPCs as a diabetic nephropathy treatment.
Testimonials Read More
As a former producer on a prominent TV news franchise, I met and got calls from publicists on a daily basis. While I have good relationships with several of them, Arlene is one of the few whom I truly trust and respect. So it was a no-brainer that when it came time to promote my book, Healing Herbal Soups, I would enlist Arlene to do the PR. Not surprisingly, she delivered with flying colors.
Genevieve Wong
Producer | Writer | Journalist
As the inventor of ULTRA-TOOTH and partner of Biodent, Inc. I want to categorically state that our experience with AHPR, Inc. -Arlene Howard PR has been beyond expectations. They deliver what they promise in the exact time frame. They have significantly raised our media profile. Their entire team's work ethics are exceptional. I have had prior PR experiences that fell far short of the promises made but not AHPR. In my book they are the best in the business!
Sargon Lazaroff
Biodent, Inc.
“Arlene Howard and her expert team are the perfect partners for Cliffside Malibu and our public relations efforts. AHPR went beyond our expectations in offering us personalized attention and creative ideas that put our business at the top of the list when media outlets need experts in the field of addiction. Our higher profile is due to their expertise, tenacity and wide-reaching media relationships. The AHPR team members are passionate about their work. I would recommend Arlene Howard Public Relations without hesitation to anyone who is looking achieve greater visibility with dedicated professionals who know their way around the media.”
Richard Taite
CEO and Founder: Cliffside Malibu Treatment Center